Who We Are
Patients are at the beginning, middle, and heart of all we do.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on Central Nervous System (CNS) disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.
What We Believe
Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.
Where We’re Starting
Our initial work is focused on Central Nervous System (CNS) disorders. We are proud to be partnering with Dr. Jeanne-Marie Lecomte and Prof. Jean-Charles Schwartz, co-founders of French company Bioprojet SCR (Bioprojet), to develop, register, and market the drug pitolisant, a selective histamine H3-receptor antagonist/inverse agonist for the potential treatment of adult narcolepsy. Currently, no H3-receptor antagonist/inverse agonist has been approved by the US Food & Drug Administration (FDA).
We believe there is tremendous potential in this receptor and we are both proud and excited to be a part of the prospective novel treatments it might offer.
IMPORTANT SAFETY INFORMATION
In clinical trials conducted in patients with narcolepsy, the most frequent adverse drug reactions (ADRs) reported with pitolisant were insomnia (8.4%), headache (7.7%), nausea (4.8%), anxiety (2.1%), irritability (1.8%), dizziness (1.4%), depression (1.3%), tremor (1.2%), sleep disorders (1.1%), fatigue (1.1%), vomiting (1.0%), vertigo (1.0%), dyspepsia (1.0%), weight increase (0.9%), and upper abdominal pain (0.9%). Pitolisant is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and in women breastfeeding their children.
Our leadership team is comprised of industry veterans with years of experience and the tools necessary to successfully and expeditiously direct needed drugs through the regulatory approval process and deliver them to the patients who need them.